Jessica Sw Borgers

12PUBLICATIONS
52CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyPredictive and prognostic markersAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 13, 2026
Decitabine reverses innate immune gene suppression in rare melanomas.

|Feb 05, 2026
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy.

Divya Lenkala, Jessica Kohler, Brian McCarthy

|Aug 05, 2025
Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Jessica S W Borgers, Divya Lenkala, Victoria Kohler

|Jun 27, 2025
Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update.

Jessica S W Borgers, Theresa M Medina, William A Robinson

|Jan 03, 2025
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Jessica S W Borgers, Divya Lenkala, Victoria Kohler

|Jun 30, 2024
Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.

Jessica S W Borgers, Tineke J van Wesemael, Kyra A Gelderman

Pageof 2

Frequent Collaborators

4 joint publications

Richard P Tobin

4 joint publications

John B Haanen

3 joint publications

Emily K Jackson

3 joint publications

Sebastian Hymson